Solid Biosciences, Inc. (SLDB)
9.72
-0.17
(-1.72%)
USD |
NASDAQ |
Aug 26, 16:00
9.70
-0.02
(-0.21%)
After-Hours: 07:53
Solid Biosciences Net Income (Quarterly) : -54.80M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -54.80M |
| March 31, 2026 | -56.74M |
| December 31, 2025 | -49.79M |
| September 30, 2025 | -45.78M |
| June 30, 2025 | -39.48M |
| March 31, 2025 | -39.28M |
| December 31, 2024 | -42.60M |
| September 30, 2024 | -32.72M |
| June 30, 2024 | -25.07M |
| March 31, 2024 | -24.30M |
| December 31, 2023 | -20.34M |
| September 30, 2023 | -20.98M |
| June 30, 2023 | -24.63M |
| March 31, 2023 | -30.07M |
| December 31, 2022 | -15.15M |
| September 30, 2022 | -20.41M |
| June 30, 2022 | -25.09M |
| March 31, 2022 | -25.33M |
| December 31, 2021 | -18.61M |
| September 30, 2021 | -17.98M |
| Date | Value |
|---|---|
| June 30, 2021 | -18.70M |
| March 31, 2021 | -16.90M |
| December 31, 2020 | -21.36M |
| September 30, 2020 | -21.25M |
| June 30, 2020 | -18.99M |
| March 31, 2020 | -26.69M |
| December 31, 2019 | -31.86M |
| September 30, 2019 | -29.26M |
| June 30, 2019 | -26.52M |
| March 31, 2019 | -29.58M |
| December 31, 2018 | -21.92M |
| September 30, 2018 | -19.02M |
| June 30, 2018 | -17.98M |
| March 31, 2018 | -15.88M |
| December 31, 2017 | -14.49M |
| September 30, 2017 | -13.50M |
| June 30, 2017 | -11.31M |
| March 31, 2017 | -13.88M |
| December 31, 2016 | -8.519M |
| March 31, 2016 | -2.991M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 54.80M |
| EPS Diluted (Quarterly) | -0.3814 |
| Enterprise Value | 663.66M |
| Earnings Yield | -19.63% |
| Normalized Earnings Yield | -19.22 |